- Home
- NVGS vs ELVN Comparison
NVGS vs ELVN Comparison
Compare NVGS & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- ELVN
- Stock Information
- Founded
- NVGS 1997
- ELVN 2016
- Country
- NVGS United Kingdom
- ELVN United States
- Employees
- NVGS N/A
- ELVN N/A
- Industry
- NVGS Marine Transportation
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- NVGS Consumer Discretionary
- ELVN Health Care
- Exchange
- NVGS Nasdaq
- ELVN Nasdaq
- Market Cap
- NVGS 957.8M
- ELVN 1.1B
- IPO Year
- NVGS N/A
- ELVN 2020
- Fundamental
- Price
- NVGS $13.22
- ELVN $19.86
- Analyst Decision
- NVGS Strong Buy
- ELVN Strong Buy
- Analyst Count
- NVGS 3
- ELVN 5
- Target Price
- NVGS $22.00
- ELVN $38.20
- AVG Volume (30 Days)
- NVGS 270.7K
- ELVN 242.7K
- Earning Date
- NVGS 03-12-2025
- ELVN 03-13-2025
- Dividend Yield
- NVGS 1.51%
- ELVN N/A
- EPS Growth
- NVGS 8.18
- ELVN N/A
- EPS
- NVGS 1.19
- ELVN N/A
- Revenue
- NVGS $566,679,000.00
- ELVN N/A
- Revenue This Year
- NVGS $3.48
- ELVN N/A
- Revenue Next Year
- NVGS $1.14
- ELVN N/A
- P/E Ratio
- NVGS $11.08
- ELVN N/A
- Revenue Growth
- NVGS 2.90
- ELVN N/A
- 52 Week Low
- NVGS $13.05
- ELVN $15.96
- 52 Week High
- NVGS $18.18
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- NVGS 26.50
- ELVN 44.82
- Support Level
- NVGS $13.15
- ELVN $18.36
- Resistance Level
- NVGS $14.47
- ELVN $22.12
- Average True Range (ATR)
- NVGS 0.36
- ELVN 1.25
- MACD
- NVGS -0.00
- ELVN -0.14
- Stochastic Oscillator
- NVGS 11.85
- ELVN 34.72
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture).
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.